公开(公告)号：WO2005029067A3

公开(公告)日：2005-08-18

申请号：PCT/JP2004011741

申请日：2004-08-10

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

IPC: C07K14/47 ,  C12N9/10 ,  C12Q1/68 ,  G01N33/574 ,  G01N33/48

CPC classification number: C12Q1/6886 ,  C07K14/4702 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2500/04

Abstract: Compositions and objective methods for detecting, diagnosing, and treating breast cancer (BRC) are described herein. In particular, the present invention describes three BRC-associated genes, referred to herein as A5657, B9769, and C7965, up-regulated in BRC cells as compared to normal cells. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells; in an alternate embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates among BRC cells, between DCIS cells and IDC cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of breast cancer, methods of treating breast cancer and methods for vaccinating a subject against breast cancer.

Abstract translation: 本文描述了用于检测，诊断和治疗乳腺癌（BRC）的组合物和客观方法。 特别地，本发明描述了与正常细胞相比，在BRC细胞中上调的三种BRC相关基因（本文称为A5657，B9769和C7965）。 在一个实施方案中，诊断方法包括确定区分BRC细胞和正常细胞的BRC相关基因的表达水平; 在替代实施方案中，诊断方法包括确定区分BRC细胞，DCIS细胞和IDC细胞之间的BRC相关基因的表达水平。 本发明进一步提供了筛选用于治疗乳腺癌的治疗剂的方法，以及用于治疗乳腺癌的方法以及接种受试者抵抗乳腺癌的方法。

公开(公告)号：WO2005029089A3

公开(公告)日：2005-06-02

申请号：PCT/JP2004013718

申请日：2004-09-14

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

IPC: G01N33/574 ,  G01N33/68

CPC classification number: G01N33/689 ,  G01N2800/364

Abstract: Disclosed are methods of diagnosing ovarian endometriosis using an antibody against the TFPI-2 protein. According to the present invention, this protein is detected at higher levels in the serum of subjects suffering from endometriosis as compared to normal control subjects and thus may serve as diagnostic marker and therapeutic target for ovarian endometriosis. In addition to methods of diagnosing ovarian endometriosis, the present invention provides kits for performing the diagnosis.

Abstract translation: 公开了使用针对TFPI-2蛋白的抗体诊断卵巢子宫内膜异位症的方法。 根据本发明，与正常对照受试者相比，在患有子宫内膜异位症的受试者的血清中检测到该蛋白质较高，因此可作为卵巢子宫内膜异位症的诊断标志物和治疗靶标。 除了诊断卵巢子宫内膜异位症的方法之外，本发明提供用于进行诊断的试剂盒。

公开(公告)号：WO2004076623A3

公开(公告)日：2004-12-23

申请号：PCT/JP2004002446

申请日：2004-02-27

Applicant: ONCOTHERAPY SCIENCE INC ,  JAPAN AS REPRESENTED BY THE PR ,  NAKAMURA YUSUKE ,  FURUKAWA YOICHI

Inventor： NAKAMURA YUSUKE ,  FURUKAWA YOICHI

IPC: A61K48/00 ,  C12N20060101 ,  C12N15/113 ,  C12N15/12 ,  C12N15/11

CPC classification number: C12N15/1135 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y201/01043

Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a ZNFN3A1 siRNA. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumer cell, for example liver or colon cancer cell, particularly HCC or colorectal adenocarcinoma.

Abstract translation: 本发明的特征在于通过使细胞与ZNFN3A1 siRNA的组合物接触来抑制癌细胞生长的方法。 治疗癌症的方法也在本发明的范围内。 本发明还包括可用于所提供的方法的产品，包括核酸序列和载体以及包含它们的组合物。 本发明还提供抑制肿瘤细胞的方法，例如肝脏或结肠癌细胞，特别是HCC或结肠直肠腺癌。

公开(公告)号：WO2004031775A3

公开(公告)日：2004-10-14

申请号：PCT/JP0310339

申请日：2003-08-14

Applicant: ONCOTHERAPY SCIENCE INC ,  JAPAN AS REPRESENTED BY THE PR ,  NAKAMURA YUSUKE ,  FURUKAWA YOICHI

Inventor： NAKAMURA YUSUKE ,  FURUKAWA YOICHI

IPC: A61K39/00 ,  A61P35/04 ,  C12Q1/68 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C12N15/11

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/136 ,  G01N33/5023 ,  G01N33/57419 ,  G01N2500/04

Abstract: Disclosed are methods of identifying agents for treating metastatic lesions of colorectal cancer. Also disclosed are methods for treating metastatic lesions of colorectal cancer and preventing metastasis of colorectal cancer.

Abstract translation: 公开了鉴定用于治疗结直肠癌的转移性病变的药剂的方法。 还公开了用于治疗结肠直肠癌的转移性病变和预防结肠直肠癌转移的方法。

公开(公告)号：WO2004020668A3

公开(公告)日：2004-06-17

申请号：PCT/JP0310591

申请日：2003-08-21

Applicant: ONCOTHERAPY SCIENCE INC ,  JAPAN GOVERNMENT ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

IPC: C07K16/30 ,  C12Q1/68 ,  A61K31/7088 ,  A61K39/395 ,  C07K16/28 ,  C12N15/11

CPC classification number: C07K16/30 ,  C07K2317/34 ,  C07K2317/732 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/136

Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject, comprising administering to the subject an effective amount of an antibody against FZD10 protein or a fragment thereof is provided.

Abstract translation: 公开了使用差异表达基因检测滑膜肉瘤的方法。 还公开了鉴定用于治疗滑膜肉瘤的药剂的方法。 此外，提供了用于治疗或预防受试者中与卷曲蛋白同系物10（FZD10）相关的疾病的方法，其包括向受试者施用有效量的抗FZD10蛋白或其片段的抗体。

公开(公告)号：WO2013109388A8

公开(公告)日：2013-09-26

申请号：PCT/US2012071434

申请日：2012-12-21

Applicant: ONCOTHERAPY SCIENCE INC

Inventor： MATSUO YO ,  HISADA SHOJI ,  NAKAMURA YUSUKE ,  AHMED FERYAN ,  WALKER JOEL R ,  HUNTLEY RAYMOND

IPC: A61K31/4745 ,  C07D471/04

CPC classification number: A61K31/5377 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/506 ,  C07D471/04

Abstract: The present invention directs a compound represented by formula (I).

Abstract translation: 本发明指出了由式（I）表示的化合物。

公开(公告)号：WO2008072777A3

公开(公告)日：2008-07-31

申请号：PCT/JP2007074359

申请日：2007-12-12

Applicant: ONCOTHERAPY SCIENCE INC ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: Disclosed herein is a method for determining kinase activity of TTK for EGFR and methods of screening for modulators of this kinase activity. Also disclosed are methods and pharmaceutical compositions for preventing and/or treating lung cancer that use or include such modulators. Methods for diagnosing lung cancer using the kinase activity of TTK for EGFR protein as an index as well as methods for assessing and prognosing lung cancer are also provided.

Abstract translation: 本文公开了确定EGFR的TTK的激酶活性的方法和筛选该激酶活性的调节剂的方法。 还公开了用于预防和/或治疗使用或包括这种调节剂的肺癌的方法和药物组合物。 还提供了使用TTK对EGFR蛋白的激酶活性作为指标诊断肺癌的方法以及肺癌的评估和预后的方法。

公开(公告)号：WO2007013670A3

公开(公告)日：2007-08-16

申请号：PCT/JP2006315341

申请日：2006-07-26

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

IPC: C12Q1/68 ,  C07K16/32 ,  C12N15/113

CPC classification number: C12N15/1137 ,  C12N15/1135 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: The present application provides novel human gene GALNT6 whose expression is markedly elevated in breast cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of breast cancers, as target molecules for developing drugs against the disease, such as siRNAS, and for attenuating cell growth of breast cancer.

Abstract translation: 本申请提供了在乳腺癌中表达显着升高的新型人基因GALNT6。 由该基因编码的基因和多肽可用于例如乳腺癌的诊断，作为用于开发针对该疾病的药物的靶分子，例如siRNAS，以及用于减弱乳腺癌的细胞生长。

公开(公告)号：WO2006085684A3

公开(公告)日：2007-03-29

申请号：PCT/JP2006302684

申请日：2006-02-09

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N2500/00

Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. In particular, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer.

Abstract translation: 本文描述了膀胱癌（BLC）检测和诊断的客观方法。 在一个实施方案中，诊断方法涉及确定鉴别BLC细胞和正常细胞的BLC相关基因的表达水平。 本发明还提供了使用具有淋巴结转移的膀胱癌细胞中具有独特改变的表达模式的BLC相关基因来预测和预防膀胱癌转移的手段。 最后，本发明提供筛选可用于治疗膀胱癌的治疗剂，治疗膀胱癌的方法和接种疫苗接种膀胱癌的方法。 特别地，本申请提供了新的人基因C2093，B5860Ns和C6055，其表达在膀胱癌中显着升高。 由该基因编码的基因和多肽可用于例如膀胱癌的诊断，作为用于开发针对该疾病的药物的靶分子，以及用于减轻膀胱癌的细胞生长。

公开(公告)号：WO2005029089A9

公开(公告)日：2006-05-04

申请号：PCT/JP2004013718

申请日：2004-09-14

Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA

IPC: G01N33/574 ,  G01N33/68

CPC classification number: G01N33/689 ,  G01N2800/364

Abstract: Disclosed are methods of diagnosing ovarian endometriosis using an antibody against the TFPI-2 protein. According to the present invention, this protein is detected at higher levels in the serum of subjects suffering from endometriosis as compared to normal control subjects and thus may serve as diagnostic marker and therapeutic target for ovarian endometriosis. In addition to methods of diagnosing ovarian endometriosis, the present invention provides kits for performing the diagnosis.

Abstract translation: 公开了使用针对TFPI-2蛋白的抗体诊断卵巢子宫内膜异位症的方法。 根据本发明，与正常对照受试者相比，在患有子宫内膜异位症的受试者的血清中检测到该蛋白质较高，因此可作为卵巢子宫内膜异位症的诊断标志物和治疗靶标。 除了诊断卵巢子宫内膜异位症的方法之外，本发明提供用于进行诊断的试剂盒。